Scottish no for Bayer's Nexavar prompts call for cancer drugs fund in Scotland
This article was originally published in Scrip
Executive Summary
The health technology assessment body for Scotland, the Scottish Medicines Consortium (SMC), has again rejected Bayer's Nexavar (sorafenib) for use on the Scottish NHS for treating hepatocellular carcinoma (HCC). The drug is available in England through the interim Cancer Drugs Fund, and critics of the SMC are now suggesting that Scotland too must set up a mechanism to address poor uptake of cancer treatment.